ABSTRACT
Rifampicin is an essential drug in the present treatment of tuberculosis. On some occasions, it cannot be used due to severe adverse effects. Rifabutin is a drug of the same family, with a similar activity and difference adverse effects. This study describes the beneficial results of the substitution of rifampicin with rifabutin in patients with severe toxicity.
Subject(s)
Antibiotics, Antitubercular/adverse effects , Antibiotics, Antitubercular/therapeutic use , Rifabutin/therapeutic use , Rifampin/adverse effects , Tuberculosis/drug therapy , Adult , Aged , Female , Humans , Male , Middle AgedABSTRACT
La rifampicina es un fármaco esencial en el tratamiento actual de la tuberculosis. En algunas ocasiones no se puede utilizar por efectos adversos graves. La rifabutina es un fármaco de la misma familia, con una actividad similar y efectos adversos diferentes. En este estudio se describen los resultados beneficiosos de la sustitución de rifampicina por rifabutina en pacientes con toxicidad intensa (AU)
Rifampicin is an essential drug in the present treatment of tuberculosis. On some occasions, it cannot be used due to severe adverse effects. Rifabutin is a drug of the same family, with a similar activity and difference adverse effects. This study describes the beneficial results of the substitution of rifampicin with rifabutin in patients with severe toxicity (AU)
Subject(s)
Male , Female , Adult , Middle Aged , Humans , Rifabutin/pharmacokinetics , Rifampin/adverse effects , Tuberculosis, Pulmonary/drug therapy , Retrospective Studies , HIV Infections/complications , Mycobacterium tuberculosisSubject(s)
Arthritis, Infectious/microbiology , Sternoclavicular Joint , Tuberculosis, Osteoarticular , Aged , Humans , MaleABSTRACT
No disponible
